The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter

被引:344
作者
Pecoits, R
Lindholm, B
Stenvinkel, P
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Clin Sci, Div Renal Med, Stockholm, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Dept Clin Sci, Div Baxter Novum, Stockholm, Sweden
关键词
atherosclerosis; chronic kidney disease; congestive heart failure; inflammation; malnutrition; MIA syndrome;
D O I
10.1093/ndt/17.suppl_11.28
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
The majority of patients starting dialysis already have signs of advanced atherosclerosis, and the risk factors for cardiovascular morbidity and mortality seen in patients with end-stage renal disease (ESRD) develop with the disease progression. Therefore, the predialysis period is the ideal time to start therapeutic interventions. Traditional risk factors alone may not adequately predict cardiovascular disease (CVD) outcome in patients with ESRD. Inflammation has been identified as playing a key role in atherosclerotic CVD. Pro-inflammatory cytokines are pivotal to the inflammation that is associated with malnutrition and atherosclerosis in ESRD. Malnutrition may worsen patient outcome by aggravating existing inflammation and heart failure, accelerating atherosclerosis and increasing susceptibility to infection. Atherosclerosis is itself a major risk factor for CVD mortality. Moreover, inflammation is associated with congestive heart failure. Strong associations between malnutrition, inflammation and atherosclerosis in this patient population suggest the presence of a syndrome we have called malnutrition, inflammation, and atherosclerosis (MIA), which is associated with an exceptionally high mortality rate.
引用
收藏
页码:28 / 31
页数:4
相关论文
共 34 条
[1]   Interleukin-6 levels are inversely correlated with heart rate variability in patients with decompensated heart failure [J].
Aronson, D ;
Mittleman, MA ;
Burger, AJ .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2001, 12 (03) :294-300
[2]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[3]   Inflammation, CRP, calcium overload and a high calcium-phosphate product:: a 'liaison dangereuse' [J].
Brancaccio, D ;
Tetta, C ;
Gallieni, M ;
Panichi, V .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (02) :201-203
[4]   Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].
Cheung, AK ;
Sarnak, MJ ;
Yan, GF ;
Dwyer, JT ;
Heyka, RJ ;
Rocco, MV ;
Teehan, BP ;
Levey, AS .
KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362
[5]  
Coresh J, 1998, J Am Soc Nephrol, V9, pS24
[6]   The role of tumor necrosis factor in the pathophysiology of heart failure [J].
Feldman, AM ;
Combes, A ;
Wagner, D ;
Kadakomi, T ;
Kubota, T ;
Li, YY ;
McTiernan, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (03) :537-544
[7]   The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (01) :53-61
[8]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[9]   Elevated plasma F2-isoprostanes in patients on long-term hemodialysis [J].
Handelman, GJ ;
Walter, MF ;
Adhikarla, R ;
Gross, J ;
Dallal, GE ;
Levin, NW ;
Blumberg, JB .
KIDNEY INTERNATIONAL, 2001, 59 (05) :1960-1966
[10]   CONGESTIVE-HEART-FAILURE IN DIALYSIS PATIENTS - PREVALENCE, INCIDENCE, PROGNOSIS AND RISK-FACTORS [J].
HARNETT, JD ;
FOLEY, RN ;
KENT, GM ;
BARRE, PE ;
MURRAY, D ;
PARFREY, PS .
KIDNEY INTERNATIONAL, 1995, 47 (03) :884-890